PALMITOYLETHANOLAMIDE 400MG X 90 CAPSULES

BREAKTHROUGH NATURAL SUPPORT FOR:
1.  ITCHING CAUSED BY A SENSITIVITY TO ENVIRONMENTAL ALLERGENS
2.  JOINT RELIEF
3.  COGNITIVE HEALTH 
MICRONISED FOR OPTIMUM POTENCY
ONLY FORM FORMULATED SPECIFICALLY FOR ANIMALS TO ENSURE MAXIMUM BENEFITS
NO FILLERS, BINDERS, GLUES OR CHEMICAL ADDITIVES OF ANY KIND.
ITCHY SKIN
Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study
Summary: 
66% of dogs benefited from micronised PEA supplementation, in terms of reduced itching and improved quality of life after 8 weeks.
JOINT HEALTH
Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?
Summary: 
Supplementation with micronised PEA shows promise for managing chronic pain, including joint pain, in dogs, cats and horses.
Oral Supplementation with Ultramicronised Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report
Summary: 
BRAIN AND COGNITIVE FUNCTION
Successful and Unsuccessful Brain Aging in Pets
Summary: 
In various in vitro and animal models of neurodegenerative conditions and senile dementia, PEA exhibits anti-inflammatory and neuroprotective effects, and supports improved cognitive performance in elderly animals.
PAIN MANAGEMENT
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis (in humans)
Summary: 
The study assessed the safety, tolerability, and efficacy of palmitoylethanolamide (PEA) in 111 adults with mild to moderate knee osteoarthritis. Improvements were seen in all measured outcomes (joint pain, stiffness, and function) using the WOMAC sub-domains, suggesting that PEA is effective in reducing symptoms of knee osteoarthritis and improving quality of life. 
(PEA is human food grade quality.)
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis
Summary: 
The study on palmitoylethanolamide included a total of 610 participants who were suffering from various chronic pain conditions involving nerves, muscles, joints and other parts of the body.